Galapagos « Terug naar discussie overzicht

KOERS GALAPAGOS 2015

16.480 Posts, Pagina: « 1 2 3 4 5 6 ... 302 303 304 305 306 307 308 309 310 311 312 ... 820 821 822 823 824 » | Laatste

Omlaag ↓

[verwijderd] 8 mei 2015 20:12

Er is van meerdere kanten geopperd dat ze mogelijk kansrijke moleculen of onderzoeksprogrammas opkopen, misschien is een kleine overname dan wel goedkoper. Er zijn tig bedrijven met een marktwaarde < 100 miljoen, als het dan toch over eeuwige roem gaat, als iemand dit goed voorspelt verdien je dst zeker :) Of gaan ze het allemaal nodig hebben voor de 2 programmas die ze zelf op de markt willen brengen....

[verwijderd] 8 mei 2015 20:19

quote:
chicken little schreef op 8 mei 2015 19:34:
zie ik daar staan $42.43??

Dit is de richtprijs. Veel interesse wordt die hoger, weinig wordt die lager.

[verwijderd] 8 mei 2015 20:23

Waarom zouden ze geld verspillen aan overnames? Goede moleculen zijn onbetaalbaar; prut is er genoeg te koop. Daarnaast hebben ze zelf één van de beste discovery platforms die er bestaan.

fc

Daarnaast:
The principal purposes of the global offering are to increase our financial flexibility to advance our clinical pipeline, create a public market for our securities in the United States and facilitate our future access to the U.S. public equity markets. We currently expect to use the net proceeds from the global offering as follows:

. approximately $80 million to advance our CF program combination therapy GLPG1837, GLPG2222 and a second corrector candidate expected to be identified later in 2015) in CF until the end of Phase 2 clinical development;

. approximately $65 million to advance our IBD program (GLPG1205) until the end of Phase 2 clinical development; and

. approximately $30 million to advance the discovery and development of our earlier stage programs, including our IPF program (GLPG1690).

We expect to use the remainder of any net proceeds from the global offering for working capital and other general corporate purposes.

Read more: www.nasdaq.com/markets/ipos/company/g...

egeltjemetstekel 8 mei 2015 20:30

quote:
chicken little schreef op 8 mei 2015 19:34:
zie ik daar staan $42.43??

ja precies!
Dat is handig want dan kan j leek mooi verifiëren op z'n raad de koers lijstje wie dat goed geraden heeft. ;-)

Maar donderdag 14 mei Hemelvaartsdag gaan we het dus beleven.
Ik ben benieuwd.

diederique 8 mei 2015 20:32

Biotech to Remain Strong Because Science is Solid, CEOs Say

Messrs. Leschly and Schenkein said the surge of biotech IPOs and the rise in the stock of many of those companies doesn’t mean the sector is in a bubble.

What once seemed like science fiction–for example, using a virus to deliver new genes to a patient’s body–is now reality, and investors want to be part of it every bit as much as dangerously sick patients do.

“A decade ago, stuff just didn’t get to market,” Mr. Schenkein said. “In the 2000s, most drugs failed because they didn’t work. But the science has changed dramatically.”

blogs.wsj.com/venturecapital/2015/05/...

[verwijderd] 8 mei 2015 20:41

Wij van wc-eend....

Sentiment 8 mei 2015 20:54

quote:
egeltjemetstekel schreef op 7 mei 2015 03:35:
ik vond op marketwatch.com een pagina over galapagos
er wordt gemeld dat het nu nog pre-ipo is op de nasdag
er staat een prijs van $42.43 usdollar bij (weet niet of dat al up to date is)

verder niet veel info denk ik

maar hier is de link: www.marketwatch.com/investing/stock/G...

Zal het dan toch $42,43 worden???

[verwijderd] 8 mei 2015 21:10

quote:
TheBateman schreef op 8 mei 2015 19:41:
42,43 dollar is Euro 37.7752

als het 37.7752 zou zijn, dan heeft mick jagger juist geraden.

[verwijderd] 8 mei 2015 21:11

quote:
Sentiment schreef op 8 mei 2015 20:54:
[...]Zal het dan toch $42,43 worden???

Volgens mij was dat simpelweg de slotkoers op 4 mei

mickjagger2 8 mei 2015 21:15

quote:
grrrrrrrrrrrr pffffff zucht schreef op 8 mei 2015 21:10:
[...]
als het 37.7752 zou zijn, dan heeft mick jagger juist geraden.

Its only rock and roll and i like it..

egeltjemetstekel 8 mei 2015 22:31

Dat is mooi
Maar ik had de dollarkoers goed
Kwam alleen op een ander euro bedrag omdat
De dollar euro koers toen anders was dan nu
(Heb ook nog een halve cent naar boven afgerond)
En die dollar euro koers is op moment van ipo vast weer anders
Dus het blijft afwachten
Het zal me benieuwen....
Maar ik gun het jou wel hoor mick!

NielsjeB 8 mei 2015 23:00

quote:
asti schreef op 8 mei 2015 21:11:
[...]
Volgens mij was dat simpelweg de slotkoers op 4 mei

Exactly. Jongens, er is hier uitgebreid gepost dat de IPO zoals ingediend door Galapagos simpelweg de slotkoers van 4 mei als referentiekoers gebruikt.

Lees het volgende uit het IPO amendement 3. Rest mag ook, maar is wat veel:

Each $1.00 (€0.90) increase or decrease in the assumed public offering price of $42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the European private placement, the closing price of our ordinary shares on Euronext Amsterdam on May 4, 2015, would increase or decrease each of as adjusted cash and cash equivalents, total assets and total shareholders’ equity by approximately $4.4 (€3.9) million, assuming that the number of shares and ADSs offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions. We may also increase or decrease the number of shares and ADSs we are offering. Each increase or decrease of 1,000,000 shares and ADSs in the aggregate number of shares and ADSs offered by us would increase or decrease each of as adjusted cash and cash equivalents, total assets and total shareholders’ equity by approximately $39.5 (€35.4) million, assuming that the assumed public offering price remains the same, and after deducting underwriting discounts and commissions. Each increase of 1,000,000 shares and ADSs in the aggregate number of shares and ADSs offered by us together with a concomitant $1.00 (€0.90) increase in the assumed public offering price of $42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the European private placement, the closing price of our ordinary shares on Euro next Amsterdam on May 4, 2015, would increase each of as adjusted cash and cash equivalents, total assets and total shareholders’ equity by approximately $44.8 (€40.2) million, after deducting underwriting discounts and commissions. Each decrease of 1,000,000 shares and ADSs in the aggregate number of shares and ADSs offered by us together with a concomitant $1.00 (€0.90) decrease in the assumed public offering price of $42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the European private placement, the closing price of our ordinary shares on Euronext Amsterdam on May 4, 2015, would decrease each of as adjusted cash and cash equivalents, total assets and total shareholders’ equity by approximately $42.9 (€38.5) million, after deducting underwriting discounts and commissions. The as adjusted information discussed above is illustrative only and will adjust based on the actual public offering price, the actual number of ordinary shares and ADSs offered by us, and other terms of the global offering determined at pricing.

www.sec.gov/Archives/edgar/data/14218...

Ook het tweede stukje van de quote is interessant, er kan nl. nog aan behoorlijk wat knoppen gedraaid worden. Laten we onszelf laten verrassen, liefst aangenaam natuurlijk.

NielsjeB 8 mei 2015 23:04

quote:
FatCool schreef op 8 mei 2015 20:23:
Read more: www.nasdaq.com/markets/ipos/company/g...

Goeie link FatCool, verplicht leesvoer. Mooie samenvatting van de IPO.

NielsjeB 8 mei 2015 23:11

quote:
j leek schreef op 8 mei 2015 17:08:
[...]
Dan worden er diverse forum leden verwijderd!

Valt wel mee hoor, meer een soort ongeschreven regel. Geen probleem verder, maar verwacht dan wel de reacties zoals je ze kreeg ;)

[verwijderd] 9 mei 2015 03:37

Hey all, how about Biocartis [Brussels Stock Exchange] does it have the same potential as Galapagos? I'm not sure, bit of a gamble, what do you think?

[verwijderd] 9 mei 2015 06:29

We estimate that we will receive net proceeds from the global offering of
approximately $183.3 (€164.3) million, assuming a public offering price of
$42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the
European private placement, the closing price of our ordinary shares on Euronext
Amsterdam on May 4, 2015, after deducting underwriting discounts and commissions
and estimated offering expenses payable by us, and assuming no exercise of the
underwriters’ option to purchase additional ordinary shares and ADSs. If the
underwriters exercise in full their option to purchase additional ADSs in the
U.S. offering and additional ordinary shares in the European private placement,
we estimate that we will receive net proceeds from the global offering of
approximately $211.2 (€189.4) million, assuming a public offering price of
$42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the
European private placement, the closing price of our ordinary shares on Euronext
Amsterdam on May 4, 2015, after deducting underwriting discounts and commissions
and estimated offering expenses payable by us.

[verwijderd] 9 mei 2015 06:29

A $1.00 (€0.90) increase (decrease) in the assumed public offering price of
$42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the
European private placement would increase (decrease) our net proceeds from the
global offering by $4.4 (€3.9) million, assuming the number of shares and ADSs
offered by us, as set forth on the cover page of this prospectus, remains the
same and after deducting underwriting discounts and commissions. Each increase
or decrease of 1,000,000 shares and ADSs in the aggregate number of shares and
ADSs offered by us would increase or decrease the net proceeds to us from the
sale of the shares and ADSs we are offering by $39.5 (€35.4) million, assuming
that the assumed public offering price remains the same and after deducting
underwriting discounts and commissions. Each increase of 1,000,000 shares and
ADSs in the aggregate number of shares and ADSs offered by us together with a
concomitant $1.00 (€0.90) increase in the assumed public offering price of
$42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the
European private placement, would increase the net proceeds to us from the sale
of the shares and ADSs we are offering by $44.8 (€40.2) million, after deducting
underwriting discounts and commissions. Each decrease of 1,000,000 shares and
ADSs in the aggregate number of shares and ADSs offered by us together with a
concomitant $1.00 (€0.90) decrease in the assumed public offering price of
$42.43 per ADS in the U.S. offering and €38.05 per ordinary share in the
European private placement would decrease the net proceeds to us from the sale
of the shares and ADSs we are offering by $42.9 (€38.5) million, after deducting
underwriting discounts and commissions. The actual net proceeds payable to us
will adjust based on the actual number of shares and ADSs offered by us, the
actual public offering price and other terms of the global offering determined
at pricing.

[verwijderd] 9 mei 2015 06:30

The principal purposes of the global offering are to increase our financial
flexibility to advance our clinical pipeline, create a public market for our
securities in the United States and facilitate our future access to the U.S.
public equity markets. We currently expect to use the net proceeds from the
global offering as follows:

. approximately $80 million to advance our CF program combination therapy
(GLPG1837, GLPG2222 and a second corrector candidate expected to be identified
later in 2015) in CF until the end of Phase 2 clinical development;

. approximately $65 million to advance our IBD program (GLPG1205) until the end
of Phase 2 clinical development; and

. approximately $30 million to advance the discovery and development of our
earlier stage programs, including our IPF program (GLPG1690).

We expect to use the remainder of any net proceeds from the global offering for
working capital and other general corporate purposes.

We may also use a portion of the net proceeds to in-license, acquire or invest
in complementary technologies, products or assets, either alone or together with
a collaboration partner. However, we have no current plan, commitments or
obligations to do so.

Based on our current operational plans and assumptions, we expect that the net
proceeds from the global offering, combined with our current operating capital,
will be sufficient to support the advancement of our research and development
programs until the end of 2017. However, there can be no assurance that these
expectations will be correct.

[verwijderd] 9 mei 2015 06:31

We currently have no specific plans as to how the net proceeds from the global
offering will be allocated beyond the uses specified above, and therefore
management will retain discretion to allocate the remainder of the net proceeds
of the global offering among these uses.

This expected use of the net proceeds from the global offering represents our
intentions based upon our current plans and business conditions. As of the date
of this prospectus, we cannot predict with certainty all of the particular uses
for the net proceeds to be received upon the completion of the global offering
or the amounts that we will actually spend on the uses set forth above. The
amounts and timing of our actual expenditures and the extent of clinical
development may vary significantly depending on numerous factors, including the
progress of our development efforts, the status of and results from pre-clinical
studies and any ongoing clinical trials or clinical trials we may commence in
the future, as well as any collaborations that we may enter into with third
parties for our product candidates and any unforeseen cash needs. For example,
in the event that AbbVie does not elect to in-license filgotinib in the second
half of 2015 under our collaboration agreement with AbbVie, we may elect to use
a portion of the net proceeds from the global offering to advance filgotinib on
our own. As a result, our management will retain broad discretion over the
allocation of the net proceeds from the global offering.

Pending our use of the net proceeds from the global offering, we intend to
invest the net proceeds in a variety of capital preservation investments,
including short-term, investment-grade, interest-bearing instruments.

[verwijderd] 9 mei 2015 06:37

€38,05/$42,34 om mee te beginnen en kan $1 hoger of lager uitkomen.
Ik schat in dat de emissie overschreven zal worden en de uiteindelijke emissiekoers rond de $43 zal uitkomen.
Zeker voor degene die al langer in Galapagos zitten een prima emissie!

16.480 Posts, Pagina: « 1 2 3 4 5 6 ... 302 303 304 305 306 307 308 309 310 311 312 ... 820 821 822 823 824 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	3 jun 2024 10:51
Koers	25,480
Verschil	-0,260 (-1,01%)
Hoog	25,540
Laag	25,300
Volume	20.054
Volume gemiddeld	85.181
Volume gisteren	175.891

Galapagos nieuws

30 mei	Galapagos gaat samenwerken met Adapti...
16 mei	Galapagos creëert nieuwe inschrijving...
16 mei	Beursblik: KBC Securities zet Galapag...
16 mei	Galapagos kondigt samenwerking aan me...
07 mei	Beursblik: UBS verlaagt koersdoel Gal...
03 mei	Beursblik: hoge cashburn Galapagos
02 mei	Galapagos handhaaft verwachte cashburn
01 mei	Aandeelhouders Galapagos keuren alle ...
12 apr	KBC Securities verlaagt koersdoel Gal...
05 apr	Galapagos toont innovatieve aanpak in...

Meer ››